What Is Pyocin? Definition and What Research Reports

Definition

Pyocin is the collective name for the bacteriocins produced by Pseudomonas aeruginosa — proteinaceous agents that the bacterium makes and releases to kill other bacteria, typically strains of its own or closely related species. The term is descriptive of origin rather than of a single molecule: a pyocin may be a large, phage-tail-like particle assembled from many protein subunits, or a single soluble polypeptide chain organised into functional domains. In each case the killing activity is carried by protein, not by a small-molecule antibiotic, which is why pyocins are discussed alongside colicins and other bacteriocins in the protein and peptide antimicrobial literature. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis, or treatment.

What Class of Molecule Pyocins Belong To

Pyocins are conventionally grouped into three structural classes. The distinction matters because it determines how the molecule finds its target and how it kills.

R- and F-type pyocins are widely described as evolutionarily related to phage tail structures, while S-type pyocins share architecture with the colicin family of Escherichia coli bacteriocins: a receptor-binding region, a translocation region, and a C-terminal killing domain. Researchers solved and analysed the receptor-binding fibres of the R1 and R2 pyocins and reported that these fibres determine which target strains a given R-type particle recognises (PMID 30110933).

Where Pyocins Come From

Pyocin genes are carried on the P. aeruginosa chromosome, and expression is linked to stress and DNA-damage signalling rather than being constant. Work on ciprofloxacin exposure reported that a P. aeruginosa oligoribonuclease contributed to tolerance of the fluoroquinolone by regulating pyocin biosynthesis (PMID 28052848). A separate study of a xerC-deleted strain reported that DNA damage-inducible pyocin expression occurred independently of RecA in that background (PMID 35708338). Transcriptional control has also been mapped at the level of individual pyocins: researchers reported that the nucleoid-associated protein MvaT negatively regulated pyocin S5 expression in P. aeruginosa (PMID 39416449). Together these reports frame pyocin production as an inducible, regulated bacterial programme rather than a housekeeping function.

How the Term Is Used in Peptide and Protein Research

In peptide and protein science, "pyocin" appears mainly in three contexts.

• As a bacteriocin case study. S-type pyocins are used as tractable models for how a large protein crosses the outer membrane of a Gram-negative bacterium, a question that also bears on the delivery of other protein cargoes.
• As a specificity module. The receptor-binding fibres of R-type particles are studied as exchangeable targeting elements, because they define host range.
• As an antibacterial protein of interest. Because P. aeruginosa is a common multidrug-resistant pathogen, pyocins are examined in the preclinical antimicrobial literature.

Pyocins are not peptide hormones, growth-factor analogues, or research peptides of the type studied for metabolic or tissue-repair endpoints. They are bacterial proteins, and the literature discussed here is microbiological.

Import and Receptor Routes

Several structural studies have defined how S-type pyocins enter their target. Researchers reported that pyocin S5 import into P. aeruginosa revealed a generic mode of bacteriocin transport, using an outer-membrane receptor together with the TonB-dependent energisation system (PMID 32156826). A later study examined the structural constraints on pyocin S2 import through the ferripyoverdine receptor FpvAI and reported requirements on how the translocation region engages that receptor (PMID 38577260). These reports explain a recurring theme: pyocins commonly hijack iron-uptake receptors, which is part of why their activity is strain-selective.

What the Published Literature Reports

Beyond structure, the published work falls into characterisation, ecology, and preclinical testing.

Biochemical Characterisation

A 2015 study carried out a biophysicochemical characterisation of pyocin SA189, produced by a P. aeruginosa isolate designated SA189, and reported on its production and stability properties under the tested conditions (PMID 26691474). Such characterisation work is what establishes whether a given pyocin behaves as a defined, purifiable protein.

Role in Bacterial Population Structure

Pyocins also shape which P. aeruginosa lineages dominate. Researchers examined the role of R5 pyocin in the predominance of high-risk P. aeruginosa isolates and reported that R5 pyocin activity was associated with the competitive standing of those high-risk clones (PMID 40466418); the same work was earlier posted as a preprint describing the same question (PMID 39416193). This line of work treats pyocins as agents of intraspecies competition, not only as candidate antibacterials.

Preclinical and Production Studies

Researchers evaluated pyocin efficacy in a murine model of P. aeruginosa sepsis and reported outcomes for pyocin-treated animals compared with controls in that model (PMID 34142136). A broader assessment reviewed in vivo and in vitro data on pyocins in treating P. aeruginosa infections and reported on the activity observed across those experimental settings (PMID 36290026). On the manufacturing side, a study expressed pyocins in plants and reported that the plant-expressed proteins were active for control of P. aeruginosa in the assays performed (PMID 28973027).

Safety and Tolerability: What Studies Report

The verified literature summarised here is preclinical and microbiological. The murine sepsis work reported on pyocin administration in infected animals as an efficacy question (PMID 34142136), and the in vivo/in vitro assessment reviewed how pyocins performed across models of P. aeruginosa infection (PMID 36290026). No human clinical safety dataset for pyocins is represented in the papers cited on this page, and no adverse-event profile in people can be inferred from animal and in vitro reports. Statements about tolerability therefore remain limited to what the study models themselves measured.

Limits of the Evidence

1. Narrow spectrum by design. Pyocin killing depends on receptor recognition, so activity reported against one set of strains does not generalise to all P. aeruginosa, as the fibre and import studies illustrate (PMID 30110933, PMID 38577260).
2. Model dependence. Efficacy signals come from laboratory assays and animal infection models (PMID 34142136).
3. Production and formulation are open questions. Work on plant expression addressed how pyocins might be produced at scale rather than how they would be used clinically (PMID 28973027).

This entry is definitional. It describes what pyocins are and what the cited studies reported; it does not describe any use of these proteins in people, and it is not medical advice.

References

• Role of R5 pyocin in the predominance of high-risk Pseudomonas aeruginosa isolates (Microbiological Research, 2025)
• Role of R5 Pyocin in the Predominance of High-Risk Pseudomonas aeruginosa Isolates (bioRxiv, 2024)
• Biophysicochemical characterization of Pyocin SA189 produced by Pseudomonas aeruginosa SA189 (Brazilian Journal of Microbiology, 2015)
• Pyocin efficacy in a murine model of Pseudomonas aeruginosa sepsis (Journal of Antimicrobial Chemotherapy, 2021)
• Structure and Analysis of R1 and R2 Pyocin Receptor-Binding Fibers (Viruses, 2018)
• DNA Damage-Inducible Pyocin Expression Is Independent of RecA in xerC-Deleted Pseudomonas aeruginosa (Microbiology Spectrum, 2022)
• Pseudomonas aeruginosa Oligoribonuclease Contributes to Tolerance to Ciprofloxacin by Regulating Pyocin Biosynthesis (Antimicrobial Agents and Chemotherapy, 2017)
• Structural constraints of pyocin S2 import through the ferripyoverdine receptor FpvAI (PNAS Nexus, 2024)
• The In Vivo and In Vitro Assessment of Pyocins in Treating Pseudomonas aeruginosa Infections (Antibiotics, 2022)
• Pyocin S5 Import into Pseudomonas aeruginosa Reveals a Generic Mode of Bacteriocin Transport (mBio, 2020)
• Plant-expressed pyocins for control of Pseudomonas aeruginosa (PLoS One, 2017)
• MvaT negatively regulates pyocin S5 expression in Pseudomonas aeruginosa (Biotechnology Notes, 2022)